Nkarta Posts Narrower Loss in Q2
Nkarta ( NASDAQ:NKTX ) , a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, reported its second-quarter earnings on August 12, 2025, covering results for the period ended June 30, 2025.
Fate Therapeutics ( FATE ) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals ( ENTA ) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst ( HCAT ) Q2 Earnings and Revenues Beat Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, July 03, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( iPSC ) -derived cellular immunotherapies to patients with cancer and autoimmune ...
Why Is Fate Therapeutics ( FATE ) Up 61.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response ( PERR ). first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE ( DORIS ...
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - Neurocrine Biosciences ( NASDAQ:NBIX ) , Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. FATE, a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the ...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus ( SLE ) Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of ...
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Fate Therapeutics ( FATE ) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 17.95% and 222.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, April 29, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc.
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for ...
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Fate Therapeutics ( FATE ) Down 34.6% Since Last Earnings Report: Can It Rebound?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
Fate Therapeutics ( FATE ) Reports Q4 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.55% and 46.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
NovoCure ( NVCR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Fate Therapeutics ( FATE ) Report Negative Q4 Earnings? What You Should Know
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics to Present at Upcoming Investor Conferences - Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, Feb. 14, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc.
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 14, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( iPSC ) -derived cellular immunotherapies to patients with cancer and autoimmune ...
IDEAYA Biosciences, Inc. ( IDYA ) Reports Q4 Loss
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( iPSC ) -derived cellular immunotherapies to patients with cancer and autoimmune ...
Fate Therapeutics ( FATE ) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile ...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - Fate Therapeutics ( NASDAQ:FATE )
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies
Fate Therapeutics Announces Leadership Transition
Bob Valamehr, Ph.D. MBA, To Become President and CEO January ...
Fate Therapeutics Announces Leadership Transition - Fate Therapeutics ( NASDAQ:FATE )
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc.
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission. Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies ...
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - Fate Therapeutics ( NASDAQ:FATE )
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819.
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Fate Therapeutics ( NASDAQ:FATE )
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, ...
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
Fate Therapeutics ( FATE ) Reports Q3 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 4.76% and 249.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies ...
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - Fate Therapeutics ( NASDAQ:FATE )
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation ...
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - Fate Therapeutics ( NASDAQ:FATE )
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning ...
Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board - Skye Bioscience ( NASDAQ:SKYE )
SAN DIEGO, Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Skye Bioscience, Inc. SKYE ( "Skye" ) , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye's new Chairman of ...
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
Why Is Fate Therapeutics ( FATE ) Up 18.7% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
